Medline Reports 10% Q3 Net Sales Growth and Announces $1 Billion Share Repurchase Program
Medline (MDLN) reported strong third-quarter results, highlighted by a 10% increase in net sales compared to the same period in 2025. CEO James Boyle attributed this performance to broad-based growth across the company's operations, specifically noting that sales from Medline Brand products rose by 7%. Looking ahead, the company has provided optimistic guidance, outlining a target for high single-digit net sales growth through 2027. To enhance shareholder value, Medline also announced the launch of a new $1 billion share repurchase program, signaling management's confidence in its long-term cash flow and market position.
Tickers: $MDLN